Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Anthony M. Manning reported an exercise-and-sale transaction in the company’s common stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then completed an open-market sale of 10,000 shares at $23.11 per share on the same date.

Following these transactions, his reported direct common stock holdings were 0 shares, while a stock option position for 2,100 shares remained outstanding, with an expiration date in 2034. The filing characterizes the stock transaction as an open-market sale.

Insider Trade Summary

Net Seller: 10,000 shares ($231,100)

Net Sell 3 txns

Insider Manning Anthony M.

Role null

Sold 10,000 shs ($231K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$4.16	$42K
Sale	Common Stock	10,000	$23.11	$231K

Holdings After Transaction: Stock Option (Right to Buy) — 2,100 shares (Direct, null); Common Stock — 10,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 10,000 shares Sale price: $23.11 per share Shares exercised: 10,000 shares +5 more

8 metrics

Shares sold 10,000 shares Open-market sale of common stock at $23.11 per share

Sale price $23.11 per share Price for 10,000 common shares sold

Shares exercised 10,000 shares Common stock from option exercise at $4.16

Exercise price $4.16 per share Conversion or exercise price for stock option

Common shares after transaction 0 shares Direct common stock holdings reported after transactions

Remaining option position 2,100 shares Stock option (right to buy) following exercise

Option expiration 2034-06-12 Expiration date of remaining stock option

Net share change -10,000 shares Net buy/sell direction reported as net-sell

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), net-sell

4 terms

open-market sale financial

"Transaction action is described as an open-market sale of common stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"The Form 4 labels the M-code transaction as a derivative exercise/conversion."

Stock Option (Right to Buy) financial

"One transaction involves a Stock Option (Right to Buy) security."

net-sell financial

"The transaction summary reports a net-sell direction of -10,000 shares."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:06 PM Accepted by SEC EDGAR 06/30/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manning Anthony M.

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		M		10,000	A	$4.16	10,000	D
Common Stock	06/29/2026		S		10,000	D	$23.11	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.16	06/29/2026		M			10,000	(1)	06/12/2034	Common Stock	10,000	$0	2,100	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney

	/s/ Phil Nickson, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did GLUE director Anthony M. Manning report?

Anthony M. Manning reported exercising options and selling common stock. He exercised options for 10,000 Monte Rosa Therapeutics shares at $4.16, then sold 10,000 shares in an open-market transaction at $23.11, leaving no directly held common shares reported.

How many Monte Rosa Therapeutics (GLUE) shares did the director sell?

The director reported selling 10,000 shares of Monte Rosa Therapeutics common stock. The sale was classified as an open-market or private transaction at a reported price of $23.11 per share, fully offsetting the 10,000 shares acquired through the option exercise.

At what price did the GLUE director exercise stock options and sell shares?

He exercised stock options at $4.16 per share and sold common shares at $23.11. The exercise covered 10,000 shares of common stock, and the same 10,000 shares were then sold in an open-market transaction on the reported transaction date.

What are Anthony M. Manning’s GLUE holdings after this Form 4 transaction?

After the reported transactions, his direct common stock holdings were 0 shares. However, a stock option position for 2,100 underlying common shares remained outstanding, with the option scheduled to expire in 2034 according to the reported derivative transaction details.

Did the GLUE director retain any stock options after exercising 10,000 shares?

Yes. After exercising options for 10,000 underlying common shares, a remaining stock option covering 2,100 shares was reported. This option relates to Monte Rosa Therapeutics common stock and carries an expiration date in 2034, as disclosed in the derivative transaction entry.